We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Diaceutics Plc | LSE:DXRX | London | Ordinary Share | GB00BJQTGV64 | ORD GBP0.002 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 103.00 | 102.00 | 104.00 | 104.00 | 103.00 | 103.00 | 14,948 | 08:00:02 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Testing Laboratories | 19.5M | 724k | 0.0086 | 119.77 | 87.01M |
TIDMDXRX
RNS Number : 0886B
Diaceutics PLC
07 June 2021
7 June 2021
Diaceutics PLC
("Diaceutics" or "the Company")
PDMR Shareholding/Share Incentive Plan
Diaceutics PLC , ( AIM: DXRX), the diagnostic commercialisation company for precision testing has been notified on 4 June 2021 that Zedra Trust Company (Guernsey) Limited, the trustees of the Global Diaceutics plc 2020 Employee Benefit Trust ("EBT"), have purchased ordinary shares ("Shares") on behalf of Susanne Munksted (PDMR), in respect of her initial purchase of Shares pursuant to the Company's Global Share Incentive Plan ("Global SIP Scheme") for international employees. These purchases will be made each month until further notice.
As announced on 30 April 2021, under the SIP Scheme, the Company will match this purchase with a matched share award being the grant of a single one-off option over an equivalent number of Shares purchased by the employee, over the forthcoming period to July 2022 and subsequent 12 month periods thereafter, in the proportion of 2:1 for all purchases up to and including April 2022 and 1:1 for all purchases thereafter. The options will be formally granted in the future, expected to be within July, at an exercise price of nil.
Enquiries:
Diaceutics PLC Philip White, Chief Financial Officer Via Alma PR Stifel Nicolaus Europe Limited (Nomad & Broker) Tel: +44 (0)20 7710 7600 Ben Maddison Stewart Wallace Nick Adams Alma PR Tel: +44(0)20 3405 0205 Caroline Forde diaceutics@almapr.co.uk Robyn Fisher Kieran Breheny
About Diaceutics
At Diaceutics we believe that every patient should have access to the right treatment at the right time. We provide the world's leading pharmaceutical companies with an end-to-end solution for the launch of precision medicine diagnostics enabled by DXRX - The Diagnostic Network(R).
DXRX is the world's first diagnostic commercialisation platform for precision medicine, integrating multiple pipelines of real-world diagnostic testing data from a global network of laboratories.
Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014 1 Details of the person discharging managerial responsibilities/person closely associated ------ ------------------------------------------------------------------------------------------------- a. Name Susanne Munksted ----------------------------------------------------- 2 Reason for notification ------------------------------------------ ----------------------------------------------------- a. Position/Status Managing Director and PDMR ------------------------------------------ ----------------------------------------------------- b. Initial notification/ Initial Amendment ----------------------------------------------------- 3 Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor a. Name Diaceutics PLC ------------------------------------------ b. LEI 213800VEWQBB39ZB8J81 ------------------------------------------ ----------------------------------------------------- 4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted ------ ------------------------------------------------------------------------------------------------- a. Description of Ordinary shares of GBP 0.002 each the financial instrument, type ISIN: GB00BJQTGV64 of instrument Identification Code ------------------------------------------ ----------------------------------------------------- b. Nature of the Ongoing non-discretionary purchase of Shares transaction to be matched by the future grant of nil cost options over Shares under the Global Share Incentive Plan ("SIP") ------------------------------------------ ----------------------------------------------------- c. Price(s) and volume(s) Share purchase: ------------------------------------------ ------------------------------------------------ Price(s) Volume(s) ------------------------------------------ ----------------------- 129.00 p 111 ----------------------- ----------------------- Matching option award: Option over 222 Shares (exercise price: nil) to be awarded in July 2021 ------------------------------------------------------------------------------------------------------- d. Date of the transaction Share purchase: 28 May 2021 (Company informed 4 June 2021) Option award: To be formally entered into in July 2021 ------------------------------------------ ----------------------------------------------------- e. Place of the transaction Share Purchase: AIM Market of the London Stock Exchange Future option award: Off-Market ------------------------------------------ -----------------------------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DSHDKOBBOBKDKAK
(END) Dow Jones Newswires
June 07, 2021 13:23 ET (17:23 GMT)
1 Year Diaceutics Chart |
1 Month Diaceutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions